{rfName}
Ef

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Castaño-Milla C.Author

Share

February 25, 2025
Publications
>
Article
No

Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to Anti-TNF therapy

Publicated to:Journal Of Clinical Gastroenterology. 49 (1): 34-40 - 2015-01-01 49(1), DOI: 10.1097/MCG.0000000000000169

Authors: Castaño-Milla C; Chaparro M; Saro C; De Acosta MB; García-Albert AM; Bujanda L; Martín-Arranz MD; Carpio D; Muñoz F; Manceñido N; García-Planella E; Piqueras M; Calvet X; Cabriada JL; Botella B; Bermejo F; Gisbert JP

Affiliations

Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas - Author
Consorci Sanitari de Terrassa - Author
Hospital Clínico Universitario de Santiago - Author
Hospital de Galdakao - Author
Hospital de León; Hospital de La Santa Creu I Sant Pau - Author
Hospital Montecelo - Author
Hospital Universitario Infanta Cristina; Hospital Universitario de Fuenlabrada - Author
Hospital Universitario Infanta Sofía - Author
Hospital Universitario La Paz - Author
Hospital Universitario Reina Sofía - Author
Instituto de Investigación Sanitaria Hospital Universitario de La Princesa; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - Author
Osakidetza, Donostia University Hospital - Author
Universitat Autònoma de Barcelona - Author
See more

Abstract

Background: Data regarding the effectiveness of adalimumab (ADA) in the treatment of perianal fistula in patients with Crohn's disease (CD) naive to antitumor necrosis factor (TNF) therapy are scarce. Aim: To assess the effectiveness of ADA in the treatment of perianal fistulas in CD patients naive to anti-TNF therapy. Methods: A retrospective multicenter study was designed. The Fistula Drainage Assessment Index was used to assess the clinical response, and the Van Assche and Ng indexes to classify radiologic response (magnetic resonance imaging). Results: A total of 46 patients (83% women, 83% complex fistula) were included. At 6 months, 72% of patients responded to ADA (54% remission, 18% partial response) and at 12 months 49% responded (41% remission, 8% partial response). Among patients with complex fistula, the response rate was 66% at 6 months and 39% at 12 months. Nine patients escalated the ADA dose to 40mg weekly, 6 for partial response and 3 for absence of response. Thirty-three percent of these patients achieved remission after dose escalation. There was a good correlation between clinical and radiologic assessment of response (κ = 0.68). In the multivariate analysis, complex fistula was the only predictor of a worse response (hazard ratio 0.083; 95% confidence interval, 0.0009-0.764; P = 0.028). Adverse effects were recorded in 11% of patients. Conclusions: ADA was effective for the treatment of perianal fistulas in CD patients naive to anti-TNF drugs. We found a good correlation between clinical and radiologic assessment of therapy response.

Keywords

AdalimumabAdultAnti-inflammatory agents, non-steroidalAntibodies, monoclonal, humanizedCrohn diseaseCrohn's diseaseCutaneous fistulaFemaleHumansMagnetic resonance imagingMaleMiddle agedPerianal fistulaRectal fistulaRemissionRetrospective studiesSeverity of illness indexTumor necrosis factor-alphaYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Gastroenterology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Gastroenterology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 1.92, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 13.98 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-04, the following number of citations:

  • Scopus: 59
  • Europe PMC: 40

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 94.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 94 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 11.95.
  • The number of mentions on the social network X (formerly Twitter): 10 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Castaño Milla, Carlos) .